WOG S1011: Standard vs Extended Lymphadenectomy in Radical Cystectomy - Phase III Trial | CRSF 2024 скачать в хорошем качестве

WOG S1011: Standard vs Extended Lymphadenectomy in Radical Cystectomy - Phase III Trial | CRSF 2024

Welcome to Day 2 of the Cancer Research and Statistic Foundation’s 05th Knowledge Series for Genitourinary Cancers - Best of 2023, held on 12th May, 2024 at The Pride Aero City Delhi. This event is proudly supported by the Institute of Pulmonology Medical Research & Development and the Sunrise Oncology Centre. In this enlightening session, Dr. Shanky Singh from Chandigarh presents the findings of the WOG S1011 Phase III surgical trial, which evaluates the benefit of standard versus extended lymphadenectomy performed during radical cystectomy for muscle-invasive urothelial cancer. This trial provides vital insights into whether extended lymph node removal during surgery results in improved outcomes for patients battling bladder cancer. Key Highlights of This Session: Radical Cystectomy with Lymphadenectomy: Radical cystectomy is a common procedure for muscle-invasive bladder cancer. Lymphadenectomy, or lymph node removal, is an integral part of this surgery to prevent cancer spread. But the extent of lymph node removal—standard or extended—has been a subject of debate. Dr. Singh explains the rationale behind the WOG S1011 trial and what it aims to uncover. Standard vs Extended Lymphadenectomy: The trial compares the outcomes of patients undergoing standard lymphadenectomy (removal of a limited number of lymph nodes) versus those undergoing extended lymphadenectomy (removal of additional nodes in a wider area). The analysis focuses on survival rates, recurrence, and post-operative complications. Phase III Trial Results: Dr. Singh reveals the latest data from this multi-center trial, shedding light on the survival benefits, potential risks, and clinical relevance of performing an extended lymphadenectomy during radical cystectomy. Is it truly more beneficial for muscle-invasive urothelial cancer patients? Implications for Surgeons and Oncologists: This trial will influence surgical decisions and treatment strategies for bladder cancer. Dr. Singh discusses how the findings may shape future guidelines and practices in the surgical treatment of muscle-invasive urothelial carcinoma. Who Should Watch? This session is highly relevant for oncologists, urologists, surgeons, and medical professionals involved in cancer care, particularly in urothelial cancer. Patients and caregivers can also gain valuable insights into the ongoing research aimed at improving surgical outcomes in bladder cancer. About Cancer Research and Statistic Foundation (CRS): CRS Foundation is dedicated to advancing cancer research and fostering collaboration among experts to improve patient outcomes. The 05th Knowledge Series for Genitourinary Cancers brings together global experts to share the Best of 2023 in cancer treatment and research. About the Supporting Institutes: Institute of Pulmonology Medical Research & Development: A leading institute promoting advancements in pulmonology and oncology. Sunrise Oncology Centre: A top oncology center dedicated to innovative cancer treatments and research. Stay tuned for more sessions from the Best of 2023 series, where the latest breakthroughs in genitourinary cancer care are explored. Subscribe for updates, and follow us on social media to stay informed on the latest research and developments in cancer treatment. Hashtags: #CancerResearch #BladderCancer #RadicalCystectomy #Lymphadenectomy #WOGS1011 #CancerSurgery #UrothelialCancer #CRSFoundation #OncologyResearch #MuscleInvasiveBladderCancer #MedicalConference2024 #GenitourinaryCancers #SunriseOncologyCentre #InstituteOfPulmonology